Cabaletta Bio Selects ElevateBio as Second CDMO for Rese-cel CAR T Manufacturing

Supply chain redundancy for autologous CAR T therapies is moving from aspiration to operational requirement, and Cabaletta Bio's selection of ElevateBio as a second CDMO for resecabtagene autoleucel (rese-cel) signals how late-stage ATMP developers are structuring commercial readiness ahead of regulatory submission.

The dual-CDMO model addresses a structural vulnerability inherent to autologous cell therapy manufacturing: single-site dependency. For QA directors and supply chain leads, the addition of a second qualified manufacturer before BLA submission reduces the risk of a site-specific deviation halting patient access at the point of commercial launch. Cabaletta has not disclosed the contractual terms or the manufacturing site location for ElevateBio's role.

The manufacturing decision sits alongside a defined regulatory timeline. Cabaletta anticipates reporting data from its registrational 17-patient dermatomyositis and antisynthetase syndrome cohort in mid-2027, with a Biologics License Application submission to FDA targeted for the second half of 2027. Juvenile myositis Phase 1/2 data are expected to be included in that filing, which may support eligibility for a Priority Review Voucher under 21 CFR pediatric provisions.

Process characterisation underpins the clinical narrative. Cabaletta's CEO cited a fully-human CAR construct, weight-based dosing, and a well-characterised manufacturing process as contributors to clinical outcomes across adult and juvenile autoimmune patient populations. For process validation leads, a well-characterised process entering a second CDMO relationship implies comparability studies and technology transfer packages will be critical path items before any commercial approval.

On the clinical side, a preconditioning-free approach is being incorporated into the RESET-MG myasthenia gravis cohort, informed by emerging data from PC-free cohorts in lupus and pemphigus vulgaris. Registrational enrollment in systemic sclerosis-associated interstitial lung disease is anticipated to initiate in 4Q26, adding a third indication to the regulatory pipeline. Expansion of outpatient dosing across the RESET program, supported by safety data presented at EULAR 2026, is also a stated priority.

Cabaletta reported second quarter 2026 financial results alongside these updates; no revenue figures were disclosed in the operational summary reviewed here.

The comparability data package supporting ElevateBio's qualification as a second manufacturing site will represent a measurable checkpoint for regulatory readiness ahead of the 2H27 BLA submission window.

Source: Cabaletta Bio, Inc. press release via GlobeNewswire, August 13, 2026.